THE SOCIAL EDIT STUDIO Trademark Application

USPTO published trademark application TM99736798 for "THE SOCIAL EDIT STUDIO" covering downloadable educational materials, online courses, webinars, coaching, and training services in social media marketing and content creation. The application was filed March 31, 2026, and published for opposition April 1, 2026. This is a routine trademark publication notice initiating the standard opposition period.

Archer Command trademark application, aviation AI software, April 1st

Archer Command trademark application, aviation AI software, April 1st

Polymer Nanoparticle Compositions for NF1 Treatment

The USPTO published patent application US20260090998A1 covering methods of using block copolymer nanoparticles for delivering nucleic acids to treat Neurofibromatosis Type 1 (NF1). The application (filed October 2, 2025) names 12 inventors and discloses compositions and methods for in vivo therapeutic delivery using polymer nanoparticles.

Delayed Release IBD Treatment Composition

Aihol Corporation filed patent application US20260090996A1 for a delayed-release oral pharmaceutical composition containing mesalamine and hyaluronan layers for treating inflammatory bowel disease. The USPTO published the application on April 2, 2026, with Application No. 19399068 and a filing date of November 24, 2025. This patent covers novel multi-layer coating technology for targeted drug delivery to the colon.

Orodispersible Estetrol Dosage Unit Patent

USPTO published patent application US20260090995A1 by ESTETRA SRL covering an orodispersible solid pharmaceutical dosage unit containing estetrol particles (0.1-25 wt.%) for sublingual, buccal, or sublabial administration. The dosage unit weighs 30-1,000 mg, contains at least 100 μg of estetrol component, and is manufactured via wet granulation of particles sized 2-50 μm. Application No. 19340502 was filed September 25, 2025.

Cannabinoid Emulsion Compositions for Treating Ophthalmic Conditions

Rhodes Technologies published patent application US20260090988A1 for stable cannabinoid emulsion compositions designed for ocular delivery to treat ophthalmic conditions including glaucoma. The application, filed July 29, 2025, and published April 2, 2026, names inventors Ping Chang, Zhenze Hu, and Yuanyuan Tao. This publication represents a patent application only and does not grant enforceable patent rights.

Aspirin Oral Mucosal Formulations

USPTO published patent application US20260090985A1 for oral mucosal aspirin formulations (91-200mg micronized) with buffer and surfactant components. The application, filed by inventor James Dzandu, covers sublingual and buccal delivery formulations with pH ≤3. No regulatory obligations or compliance deadlines are imposed by this patent publication.

LifeActive Transdermal Delivery Formulations Patent Application

USPTO published patent application US20260090982A1 for LifeActive, Inc., covering transdermal delivery formulations for therapeutic agents, drugs, and nutrients. Inventors include Calvin Dexter Morris, Burgess A. Thomasson Jr., and Scott A. Jenkins. The application discloses homogeneous transdermal formulations combining weak organic acid accelerants with fatty acid microemulsions for enhanced skin absorption.

Urolithin oral care compositions patent application

USPTO published patent application US20260090966A1 for urolithin-based oral care compositions including toothpaste, mouthwash, gels, and chewing gum with therapeutic or cosmetic effects. The application covers compositions comprising urolithins, methods of treatment, and formulations with additional active ingredients such as fluoride. Inventors include Christopher L. Rinsch, Davide D'Amico, Anurag Singh, and Charlotte Tissot.

Cat Food Composition for Treating Urolithiasis and Reducing Hairballs

The USPTO published patent application US20260090571A1 for a cat food composition targeting urolithiasis (urinary stones) and hairball reduction. Inventors Nolan Z. Frantz, Angela M. Gajda, and Todd Harper developed wet and dry formulations incorporating omega-3 sources (flaxseed, fish oil), acidifiers (calcium sulfate, SAPP), methionine, taurine, and dietary fiber to achieve urine pH between 6.15-6.85 and reduce RSS struvite to ≤1.8 and RSS oxalate to ≤6.0.